A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

Inclusion Criteria: * Have a body mass index within the range of 18.0 to 32 kilograms per square meter (kg/m²) * Males who agree to follow contraceptive requirements and women of not childbearing potential * Have body weight greater than or equal to (\>=) 50 Kilograms at screening. * Must have a negative Interferon-Gamma Release Assays (IGRA) testing at screening * Must have been stopped all the prescribed medication at least 14 days prior to admission to the clinical site * Ability and willingness to abstain from alcohol, caffeine, and methylxanthine-containing beverages or food 2 days prior to admission to the clinical site * Abstain from any strenuous physical exercise from 4 days prior to admission and during confinement at the clinical site Exclusion Criteria: * Have a history of relevant drug and/or food allergies, or sensitivity to medications used in the current study * Females participants who are currently breastfeeding * Have History of alcohol abuse or drug addiction * Unable to abstain from tobacco products within the 2 days prior to admission and during confinement at the clinical site * Have Positive screen for hepatitis B surface antigen, hepatitis C virus (HCV) antibodies, or human immunodeficiency virus (HIV) 1 and 2 antibodies * Consumption of any nutrients known to modulate CYP450 enzymes activity * Are immunocompromised * Have received live vaccine(s) (including attenuated live vaccines) or Bacillus Calmette-Guérin within 28 days of screening or intend to receive them during the study * Have had any malignancy within the past 5 years